← Off-the-shelf platform
Off-the-shelf · Hemoglobinopathies · Preclinical

Partial donor chimerism, disproportionate healthy red cell output.

Permanent invisibility · Durable graft

In sickle cell disease, roughly 20–25% donor myeloid chimerism can be enough to sustain a non-sickling phenotype. In β-thalassemia, donor red cells can likewise become disproportionately enriched. A banked product does not have to fully replace the marrow to change the disease.

The access gap

Curative biology exists. Access does not.

Donor availability, manufacturing capacity, cost and treatment-centre access limit global reach — so the overwhelming majority of patients have received neither transplant nor gene therapy.

Sickle cell disease

~7.7M
people living with SCD worldwide
Low hundreds
gene therapy treatments to date
>99.9%
have not received HSCT or gene therapy

β-thalassemia

~100,000
transfusion-dependent patients worldwide
Hundreds
gene therapy treatments to date
>90%
have not received HSCT or gene therapy

Sources & caveats

Global transfusion-dependent thalassemia estimates vary by source and region; a commonly cited range is 60,000–200,000.

WHO / CDC (SCD prevalence); Thalassemia International Federation; CIBMTR / EBMT literature; public company disclosures for gene therapy uptake.

The approach

A banked, one-time infusion — no donor search.

High-level schematic of banked engineered HSPCs for hemoglobinopathies.
High-level schematic: banked engineered donor HSPCs designed for durable, transfusion-independent correction.
Path

A Middle East–first development wedge.

Regulatory route

Cell & gene therapy IND path, with global clinical development and regional access strategy.

Evidence package

Stable donor chimerism · donor red cell / erythroid output · conditioning, durability and safety.

Execution

Regional collaborations in the Middle East, where prevalence is high, then global markets.

Regulatory routes shown are planning hypotheses, not approval claims.

Next: the autologous platform → Request deck